Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasis

Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasis - clinical study for pancreatic cancer with peritoneal metastasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018878

Enrollment

Registered

2015-09-01

Start date

2015-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients with pancreatic cancer who have peritoneal metastasis diagnosed by staging laparoscopy or open laparotomy.

Interventions

Gemcitabine (800-1000mg/m2, weekly for 3 weks with 1wk rest) and nab-paclitaxel(100-125mg/m2, weekly for 3 weks with 1wk rest) plus intraperitoneal paclitaxel administration (15-20mg/m2, weekly for 3

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pancreatic adenocarcinoma histologically proven with peritoneal metastasis diagnosed using staging laparoscopy or open laparotomy, performance status 0 or 1, adequate bone marrow function, adequate liver function, adequate renal function, obtained informed consent

Exclusion criteria

Exclusion criteria: Metastasis to distant organ sites such as the liver, lungs or bone; other active concomitant malignancies; other severe medical conditions; contraindication of Gemcitabine, nab-paclitaxel or Paclitaxel, or Pregnant woman

Design outcomes

Primary

Measure	Time frame
One year survival rate	—

Countries

Japan

Contacts

Public ContactSohei SATOI MD, FACS

Kansai Medical University Department of Surgery

satoi@hirakata.kmu.ac.jp0728040101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026